The October 14 KOL event may serve as a catalyst if new efficacy/safety data or regulatory timelines for SGT-610 are discussed. Monitor for any material disclosures during or after the webcast.
Price Chart
Executive Summary
Sol-Gel Technologies announced it will host a KOL Investor Day on October 14, 2026, focused on its lead candidate SGT-610 (patidegib gel, 2%) for Gorlin Syndrome. The event features key opinion leaders and patient advocates, but no new clinical data or regulatory milestones were disclosed.
Key Facts
- KOL Investor Day scheduled for October 14, 2026 in New York, with live webcast at 12:00 p.m. ET
- Event focused on SGT-610 (patidegib gel, 2%), a Phase 3 orphan- and breakthrough-designated topical hedgehog inhibitor for Gorlin Syndrome
- Speakers include Julie Breneiser (Gorlin Syndrome Alliance), Dr. Ervin Epstein Jr., Dr. Kavita Sarin (Stanford), and Dr. Elizabeth Billingsley (Penn State)
- No new clinical data, regulatory updates, or financial guidance provided in the filing
Financial Impact
No financial figures disclosed; event is a pre-clinical-data investor education initiative
Risk Factors
- Phase 3 trial of SGT-610 may fail to meet primary or secondary endpoints
- Company has history of recurring losses and may need additional financing
- No guarantee of regulatory approval for SGT-610 in Gorlin Syndrome
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004668 |
| Document: zk2636179.htm | 0001178913-26-004668 |
| Document: 0001178913-26-004668-index-headers.html | 0001178913-26-004668 |
| Document: 0001178913-26-004668-index.html | 0001178913-26-004668 |
| Document: 0001178913-26-004668.txt | 0001178913-26-004668 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+20 | — | $68.19 (−5.29%) |
Oct 6, 2026 21d ago | 6-K | $75.64 | awaiting T+20 | — | $68.19 (−9.85%) |
Sep 30, 2026 27d ago | 6-K | $74.28 | awaiting T+20 | — | $68.19 (−8.20%) |
Sep 17, 2026 5w ago | 6-K | $64.54 $68.70 | ▲ +6.45% | ▲ +4.99% | $68.19 (+5.66%) |
Sep 14, 2026 6w ago | Insider Buy | $64.40 $68.30 | ▲ +6.06% | ▲ +3.08% | $68.19 (+5.89%) |
Sep 9, 2026 6w ago | Insider Buy | $66.79 $70.34 | ▲ +5.32% | ▲ +2.94% | $68.19 (+2.10%) |
Sep 3, 2026 7w ago | Insider Buy | $69.52 $78.95 | ▲ +13.56% | ▲ +12.96% | $68.19 (−1.91%) |
Aug 31, 2026 8w ago | Insider Buy | $69.52 $74.28 | ▲ +6.85% | ▲ +6.53% | $68.19 (−1.91%) |
Aug 20, 2026 9w ago | 6-K | $78.50 $64.54 | ▼ −17.78% | ▼ −17.78% | $68.19 (−13.13%) |
Aug 20, 2026 9w ago | Press Release | $78.50 $64.54 | ▼ −17.78% | ▼ −17.78% | $68.19 (−13.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers